Leprosy
Recent clinical, regulatory, research and industry developments relating to this disease.
An update on leprosy immunopathogenesis: systematic review.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q1 2027.
Clinical MilestonesViewHide
- 2026-05-19Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 3 StudyResults expected Q1 2027
- 2026-08-31Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in IndonesiaPrimary completion
- 2026-06-01Monitoring the Effect of Prophylactic Interventions in Contacts of Leprosy Patients Including Field-application of a Novel Immunodiagnostic Test in BangladeshPrimary completion
- 2025-12-10Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical TrialPrimary completion
- 2026-08-31ClinicalEfficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in IndonesiaPrimary completion
- 2026-06-01ClinicalMonitoring the Effect of Prophylactic Interventions in Contacts of Leprosy Patients Including Field-application of a Novel Immunodiagnostic Test in BangladeshPrimary completion
- 2026-05-19ClinicalBedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 3 StudyResults expected Q1 2027
- 2025-12-10ClinicalRab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical TrialPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes5
- Disability-Adjusted Life Years1
- Global Burden of Disease1
- Leprosy1
- Mycobacterium leprae1
- Neglected Diseases1
Leading journals2
- BMJ (Clinical research ed.)1
- Frontiers in immunology1
Leading researchers8
- Alves AK1
- Brasil TP1
- Djirmay AG1
- Dos Santos EC1
- Fall IS1
- Frota CC1
- Li WH1
- Lima KVB1
Affiliations (unnormalised)6
- Evandro Chagas Institute (IEC)1
- Federal University of Ceará (UFC)1
- National Institute of Parasitic Diseases at Chinese Center for Disease Control and Prevention1
- NHC Key Laboratory of Tropical Disease Control1
- One Health Center1
- University of Pará State (UEPA)1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.